White Pine Capital LLC held its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,475 shares of the medical equipment provider’s stock at the close of the second quarter. White Pine Capital LLC’s holdings in Zimmer Biomet Holdings were worth $446,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of ZBH. Strs Ohio grew its stake in Zimmer Biomet Holdings by 13.5% in the first quarter. Strs Ohio now owns 12,865 shares of the medical equipment provider’s stock valued at $1,570,000 after acquiring an additional 1,532 shares during the period. Klingenstein Fields & Co. LLC acquired a new position in Zimmer Biomet Holdings in the first quarter valued at about $282,000. Commerzbank Aktiengesellschaft FI grew its stake in Zimmer Biomet Holdings by 16.3% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 4,755 shares of the medical equipment provider’s stock valued at $581,000 after acquiring an additional 666 shares during the period. Webster Bank N. A. grew its stake in Zimmer Biomet Holdings by 12.0% in the first quarter. Webster Bank N. A. now owns 1,447 shares of the medical equipment provider’s stock valued at $176,000 after acquiring an additional 155 shares during the period. Finally, State Treasurer State of Michigan grew its stake in Zimmer Biomet Holdings by 0.8% in the first quarter. State Treasurer State of Michigan now owns 66,043 shares of the medical equipment provider’s stock valued at $8,065,000 after acquiring an additional 500 shares during the period. 85.48% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have issued reports on ZBH shares. Goldman Sachs Group, Inc. (The) started coverage on Zimmer Biomet Holdings in a research note on Tuesday, May 16th. They issued a “sell” rating and a $92.00 target price for the company. ValuEngine cut Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Citigroup Inc. boosted their target price on Zimmer Biomet Holdings from $108.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, June 9th. Royal Bank Of Canada upped their price objective on Zimmer Biomet Holdings from $133.00 to $140.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 21st. Finally, Cantor Fitzgerald began coverage on Zimmer Biomet Holdings in a research report on Thursday, June 29th. They set a “neutral” rating and a $137.00 price objective for the company. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $136.75.
In related news, VP Tony W. Collins sold 16,986 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.07% of the stock is currently owned by corporate insiders.
Shares of Zimmer Biomet Holdings, Inc. (ZBH) traded up 0.566% during trading on Monday, hitting $116.355. The stock had a trading volume of 83,308 shares. The company has a market capitalization of $23.53 billion, a price-to-earnings ratio of 33.140 and a beta of 1.21. Zimmer Biomet Holdings, Inc. has a 52 week low of $95.63 and a 52 week high of $133.49. The company’s 50 day moving average price is $116.26 and its 200 day moving average price is $120.83.
Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The firm had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.95 billion. During the same quarter in the previous year, the company posted $2.02 EPS. Zimmer Biomet Holdings’s revenue for the quarter was up 1.1% on a year-over-year basis. Analysts predict that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be paid a $0.24 dividend. The ex-dividend date is Thursday, September 21st. This represents a $0.96 annualized dividend and a yield of 0.83%. Zimmer Biomet Holdings’s payout ratio is 27.59%.
COPYRIGHT VIOLATION NOTICE: “Zimmer Biomet Holdings, Inc. (ZBH) Position Held by White Pine Capital LLC” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://sportsperspectives.com/2017/09/11/zimmer-biomet-holdings-inc-zbh-position-held-by-white-pine-capital-llc.html.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.